Rentschler Biopharma SE
Rentschler implements innovative learning program in collaboration with MassBioEd and WPI
EQS-News: Rentschler Biopharma SE
/ Key word(s): Alliance
Rentschler implements innovative learning program in collaboration with MassBioEd and WPI
Laupheim, Germany and Milford, MA, USA, December 07, 2022 – Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, is celebrating its 150th anniversary this year, and the company continues to evolve and grow. Adjacent to its existing facility in Milford, MA, the company has undertaken the largest expansion in its long history. The state-of-the-art Rentschler Biopharma Manufacturing Center (RBMC) will add 22,000 square feet of manufacturing cleanroom space and house four new 2,000 L single-use bioreactors, in addition to being highly automated and leveraging industry 4.0 solutions. As the company grows in terms of capacity, technology, projects, and clients, it is also growing its highly trained workforce. Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) focused exclusively on client projects. The company offers process development and manufacturing of biopharmaceuticals as well as related consulting activities, including project management and regulatory support. Rentschler Biopharma’s high quality is proven by its long-standing experience and excellence as a solution partner for its clients. A high-level quality management system, a well-established operational excellence philosophy and advanced technologies ensure product quality and productivity at each development and manufacturing step. In order to offer best-in-class formulation development along the biopharmaceutical value chain, the company has entered into a strategic alliance with Leukocare AG. Rentschler Biopharma is a family-owned company with about 1,200 employees, headquartered in Laupheim, Germany, with a second site in Milford, MA, USA. In Stevenage, UK, Rentschler Biopharma has launched a company dedicated to cell and gene therapies, Rentschler ATMP Ltd. For further information, please visit http://www.rentschler-biopharma.com. Follow Rentschler Biopharma on LinkedIn and Facebook.
07.12.2022 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. |